Wave Life Sciences Ltd. has outlined its significant clinical milestones and strategic priorities for 2025 during the J.P. Morgan Healthcare Conference. The company is advancing its RNA medicines ...

Ascendis Pharma A/S has announced its strategic roadmap and key milestones for 2025, highlighting their potential for rapid revenue growth linked to the launch of their first two Endocrinology Rare ...

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 ...

CEO Walter Klemp highlighted the official start of the Phase 3 MIRACLE trial for Annamycin, with the first patient treated and a total of 38 sites now selected worldwide. He noted, "We just announced ...